From AI-supported medical training and research tools to new technologies for mobility and drug discovery, six new companies are joining the CO-AX Accelerator at Sahlgrenska Science Park.
The cohort brings together Veta Science, Kymeon Tech, Clareo AI, Curevo health, Magnes and Vitroprobe Analytics – six companies addressing very different challenges across healthcare and life science.
“This cohort really shows the breadth of innovation we see in health and life science today. What they have in common is that they are tackling real problems with technologies that have the potential to make a difference. Our role is to help them shorten the journey from innovation to market,” says Emma Hallenberg, Director CO-AX at Sahlgrenska Science Park.
Meet the companies
Veta Science – Making research data ready for discovery
Helps life science researchers assess available data and turn fragmented datasets into harmonised, analysis-ready information, making research more efficient and reproducible.
Kymeon Tech – Improving ultrasound training with AI
Develops Sonora, combining AI-powered feedback with remote expert review to make ultrasound training more accessible and scalable.
Clareo AI – Simplifying medical device development
Develops an AI-powered platform that helps medical device startups structure their work and navigate clinical, business and regulatory requirements.
Curevo Health – Making healthcare more accessible with AI
Develops a digital healthcare platform combining AI-supported technology with doctor-led assessments to provide more accessible, personalized and efficient care.
Magnes – Supporting mobility through smart technology
Combines wearable sensors, AI-powered movement analysis and real-time feedback to support walking, mobility and rehabilitation.
Vitroprobe Analytics – Advancing drug discovery
Develops technology for analysing biomolecules at the atomic scale, helping researchers gain a deeper understanding of proteins and potential drug targets.
From technology to real-world application
With CO-AX, companies receive tailored business support and access to expertise across healthcare, industry, academia and investment. This includes help with regulatory strategy, clinical validation, market access, business development and investor readiness.
The aim is simple: to help promising companies shorten the path from innovation to market.
Next applications for CO-AX Accelerator open in January 2027.
Developing an innovative solution in health or life science?
Follow CO-AX at Sahlgrenska Science Park for updates on the next application round.